Haleon Stock Report Including Investor Information and Details

Haleon is a global leader in consumer health and wellbeing, formed after the separation from GSK in 2022.

Haleon's stock is listed on the London Stock Exchange and the Euronext Amsterdam exchange.

The company has a market capitalization of around £22 billion, making it a significant player in the consumer health and wellbeing sector.

As Haleon continues to grow and develop, investors are likely to be interested in its financial performance and future prospects.

For another approach, see: Stock Exchange

Haleon's stock performance has been quite interesting over the years. The company's stock price has decreased by -7.53% in the last 52 weeks.

Looking at the historical stock price data, we can see that the stock price has fluctuated between £8.71 and £11.42 over the past year. The 52-week high was £11.42, while the 52-week low was £8.71.

In terms of performance, Haleon's stock has underperformed the US Market, which returned 16.3% over the past year. However, it matched the US Pharmaceuticals industry, which returned -5.7% over the past year.

Here's a summary of Haleon's stock performance over the past 52 weeks:

The stock's beta is 0.23, which means its price volatility has been lower than the market average. This could be a good sign for investors looking for a relatively stable stock.

Haleon's financial data is a crucial aspect to consider when evaluating the stock. The company's revenue has been steadily increasing, reaching £11,233.00 million in the year ending 31/12/2024, up from £11,302.00 million in the previous year.

The company's profit before tax has also seen an increase, reaching £1,910.00 million in the year ending 31/12/2024, up from £1,628.00 million in the previous year.

Here's a breakdown of Haleon's financial data:

Haleon's adjusted earnings per share (EPS) have also seen a significant increase, reaching 15.80p in the year ending 31/12/2024, up from 11.40p in the previous year.

The company's price-to-earnings (P/E) ratio has decreased, reaching 23.90 in the year ending 31/12/2024, down from 28.20 in the previous year.

Haleon's return on equity (ROE) is 9.38%, indicating a reasonable return on shareholders' equity. The company's return on invested capital (ROIC) is 5.98%, indicating a moderate return on capital employed.

Here's a summary of Haleon's key financial metrics:

Haleon's dividend yield is 1.70% for the year ending 31/12/2024, indicating a relatively low dividend payout ratio. The company's dividend cover is 2.39, indicating that the dividend is covered by earnings.

Here's a breakdown of Haleon's dividend data:

Haleon's market cap is a staggering $41.61 billion, making it a significant player in the market.

The enterprise value is even higher, standing at $52.22 billion. This gives us an idea of the company's overall value, including its debt.

The trailing PE ratio is 40.79, which can be compared to the forward PE ratio of 18.12. This indicates a significant difference in the company's valuation based on past and future earnings.

Here are some key valuation ratios to consider:

The EV/EBITDA ratio is a key metric to consider, standing at 14.52. This can be compared to the EV/FCF ratio of 17.61, which provides further insight into the company's valuation.

Consider reading: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

Valuation Ratios are a crucial aspect of evaluating a company's stock. They help investors understand the relationship between the stock's price and its underlying value.

The Trailing PE ratio for Haleon is 40.79, indicating that investors are willing to pay 40.79 times the company's earnings for its stock. This ratio can be used to compare Haleon's valuation to its industry peers.

The Forward PE ratio for Haleon is 18.12, suggesting that investors expect the company's earnings to grow significantly in the future, justifying a lower price-to-earnings multiple. This ratio can be used to estimate the stock's future performance.

Here are some key Valuation Ratios for Haleon:

These ratios provide a comprehensive view of Haleon's valuation and can be used to make informed investment decisions.

Community Fair Values can be a powerful tool for investors, allowing them to see what others think a stock is worth.

You can follow the fair value set by 8 others or set your own to get alerts, giving you a sense of the market's perception of a stock's value.

Some investors find it helpful to follow the opinions of others, while others prefer to set their own fair value based on their own research and analysis.

This feature can be a great way to get a sense of the market's sentiment and make more informed investment decisions.

By following the fair value set by others or setting your own, you can stay on top of changes in the market and adjust your investment strategy accordingly.

On a similar theme: Stock Market

Haleon's stock has some impressive numbers. The open price is 9.38 USD.

The high and low prices for the day were 9.40 and 9.30 USD, respectively. The bid and offer prices are 9.34 and 9.35 USD, which is close to the previous close of 9.41 USD.

The average volume traded is 8.99 million shares, with a market capitalization of 41.64 billion USD. The company has a large number of shares outstanding, at 4.45 billion.

Here are some key metrics for Haleon:

The company has a significant free float of 3.97 billion shares, which is a good sign for investors.

Haleon is a global leader in consumer healthcare with a portfolio that includes iconic brands like Sensodyne, Voltaren, and Caladryl.

As a publicly traded company, Haleon's stock is listed on the London Stock Exchange under the ticker symbol HLN.

Haleon's history dates back to 1897 when it was founded as Reckitt & Sons in the UK.

The company went through a significant restructuring in 2021, separating its consumer health business from its food and nutrition business.

Haleon's focus is on delivering innovative solutions for everyday health and wellness needs.

The company's products are sold in over 180 countries worldwide.

Haleon's brand portfolio includes over 20 well-known brands across various categories, including pain relief, oral care, and skin care.

Haleon's revenue in 2021 was £7.6 billion.

Suggestion: Haleon Share Price Uk Pounds

Haleon stock has had an interesting ride in recent years. Its average stock price in 2025 was $9.8445, with a year open of $9.2696 and a year high of $11.3411.

The stock price fluctuated throughout the year, with a year low of $8.7200 and a year close of $9.3300. This resulted in an annual percentage change of -0.40%.

Here's a breakdown of Haleon's stock price history over the past three years:

Haleon is a consumer healthcare company that engages in the research, development, manufacture, and sale of various products in several regions. Its stock is currently trading at 8.7% below its estimated fair value.

The company's earnings are forecast to grow 6.32% per year, which is a positive sign for investors. In fact, earnings grew by 39.9% over the past year, indicating a strong performance by the company.

Haleon's stock price has been relatively stable, with a current price of £9.33. This is a significant increase from its 52-week low of £8.71.

The average volume of Haleon's stock over the past 20 days is 9.32 million shares. This indicates a moderate level of trading activity.

Haleon has a market capitalization of $41.64 billion, making it a large-cap stock. Its shares outstanding total 4.45 billion.

The company's annual dividend yield is 1.98%, with a dividend ex-date of August 15, 2025, and a pay-date of September 18, 2025.

Here's a breakdown of Haleon's key statistics: